
binx health Enters into Distribution Agreement for National Launch of the FDA-cleared binx io
binx molecular point-of-care platform poised to transform care for chlamydia and gonorrhea, the two most tested for sexually-transmitted infections
binx molecular point-of-care platform poised to transform care for chlamydia and gonorrhea, the two most tested for sexually-transmitted infections
binx positioned to “switch on care at scale” in New York, Los Angeles and Miami
Latest amendment adds important tool for student health and employers in the fight against COVID-19
Wellfleet taps binx for convenient, in-dorm sample collection and bespoke technology solutions to help arrest virus spread
binx health’s Proven Molecular io Platform Combined with SHERLOCK™ CRISPR Technology Will Enable Rapid, Accurate Testing for SARS-CoV-2 in Retail and Near-patient Settings
Binx and UPS Healthcare pair advanced infectious disease testing with superior global logistics to reach populations everywhere, starting in the United Kingdom
Study signals “real paradigm shift” in care resulting from the world’s first FDA-cleared, 30-minute, molecular point-of-care platform for the detection of chlamydia and gonorrhea
Latest FDA clearance establishes binx as the fastest dual-gender rapid test-and-treat platform for chlamydia and gonorrhea
COVID-19 pandemic has created growing backlog of millions in need of routine STI testing
binx health was featured in Fortune Magazine highlighting the io platform as not only the first and fastest FDA-cleared molecular point-of-care diagnostic for the detection of chlamydia and gonorrhea, but…